---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-008613"
form_type: "8-K"
ticker: "VTAK"
cik: "0001716621"
company_name: "Catheter Precision, Inc."
filed_at: "2024-07-03T23:59:59+00:00"
generated_at: "2026-05-31T23:31:29.448383+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Catheter Precision reports Q2 revenue of $94,840; approves 1-for-10 reverse stock split

## Summary
- Preliminary Q2 2024 revenue $94,840, including first LockeT sales ($40,500) and VIVO ($54,340).
- Six-month 2024 revenue $176,923; 15% sequential quarter-over-quarter growth.
- Board approved 1-for-10 reverse stock split effective July 15, 2024; shares reduce from 8.4M to ~839K.
- Series A Preferred conversion issued 814,228 common shares on July 1, 2024.
- New CCO Marie Claude Jaques hired in May; sales pipeline growing.

## SEC filing metadata
- accession: 0001654954-24-008613
- form_type: 8-K
- ticker: VTAK
- cik: 0001716621
- company_name: Catheter Precision, Inc.
- filed_at: 2024-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000165495424008613/0001654954-24-008613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000165495424008613/rmed_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-008613
- JSON: https://secwatch.observer/filing/0001654954-24-008613.json
- Plain text: https://secwatch.observer/filing/0001654954-24-008613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.